⚜️ Archaiforge Schema: Universal Deep Analysis Report

Subject: The Universal Diabetes Analysis (Aggregate) Status: [VERIFIED] Geometric Validation of the Metabolic/Autoimmune Cascade

The Core Epistemological Law

Structure precedes Biology. This deep analysis aggregates 76 unique Diabetes computational sweeps across the full disease substrate. It isolates the non-probabilistic structural constants shared across all disease sub-types.

Phase 1: Mission Dossier & Clinical Baseline

Date and Epoch: 2026-04-03 | 12:36 UTC
The Human Context Hypothesis: Can the thermodynamics engine successfully aggregate 76 varying typologies of Diabetes (Type 1, Type 2, MODY, Neonatal, Syndromic) to extract shared geometric constants that cross the autoimmune/metabolic boundary?
Extraction Target Scope: 76 Isolated Target Matrices

Phase 2: The Multi-Dimensional Sweep (The Raw Engine Data)

Total Geometries Swept: 548,568 isolated physical tension alignments.
Topography Breakdown:
- Type 1: 10 variants mapped
- Type 2: 23 variants mapped
- MODY: 14 variants mapped
- Neonatal: 9 variants mapped
- Microvascular: 6 variants mapped
- Syndromic/Other: 14 variants mapped

The Universal Structural Backbone (Tensors 3 Variants):
| Structural Node | Variant Intersections | Overlap % | | :--- | :--- | :--- | | NEUROD1 / Type 2 diabetes mellitus | 16 | 21.05% | | NEUROD1 / Maturity-onset diabetes of the young 6 | 15 | 19.74% | | PAX4 / Maturity-onset diabetes of the young 9 | 13 | 17.11% | | PAX4 / Type 2 diabetes mellitus | 13 | 17.11% | | PAX4 / Diabetes mellitus, ketosis-prone | 13 | 17.11% | | ABCC8 / Diabetes mellitus, permanent neonatal, 3 | 11 | 14.47% | | SLC5A2 / Renal glucosuria | 11 | 14.47% | | HNF4A / Fanconi renotubular syndrome 4 with maturity-onset diabetes of the young | 11 | 14.47% | | SLC2A4 / Type 2 diabetes mellitus | 10 | 13.16% | | MAFA / Insulinomatosis and diabetes mellitus | 10 | 13.16% | | SLC5A1 / Congenital glucose/galactose malabsorption | 10 | 13.16% | | NEUROG3 / Diarrhea 4, malabsorptive, congenital, with diabetes mellitus and combined pituitary hormone deficiency | 10 | 13.16% | | ABCC8 / Transient neonatal diabetes mellitus 2 | 9 | 11.84% | | HNF4A / Maturity-onset diabetes of the young 1 | 9 | 11.84% | | HNF4A / Type 2 diabetes mellitus | 9 | 11.84% | | EPAS1 / Erythrocytosis, familial, 4 | 9 | 11.84% | | NKX2-1 / Choreoathetosis and congenital hypothyroidism with or without pulmonary dysfunction | 9 | 11.84% | | NKX2-5 / Hypothyroidism, congenital, non-goitrous, 5 | 9 | 11.84% | | ABCC8 / Hyperinsulinemic hypoglycemia, familial, 1 | 8 | 10.53% | | ABCC8 / Leucine-induced hypoglycemia | 8 | 10.53% | | ABCC8 / Maturity-onset diabetes of the young 12 | 8 | 10.53% | | NKX2-1 / Thyroid cancer, non-medullary, 1 | 8 | 10.53% | | NKX2-5 / Hypoplastic left heart syndrome 2 | 8 | 10.53% | | NKX2-5 / Ventricular septal defect 3 | 8 | 10.53% | | NKX2-5 / Atrial septal defect 7, with or without atrioventricular conduction defects | 8 | 10.53% | | NKX2-5 / Conotruncal heart malformations | 8 | 10.53% | | NKX2-5 / Tetralogy of Fallot | 8 | 10.53% | | ABCG8 / Gallbladder disease 4 | 7 | 9.21% | | GATA1 / Thrombocytopenia with beta-thalassemia, X-linked | 7 | 9.21% | | SLC37A4 / Glycogen storage disease 1C | 7 | 9.21% | | SLC37A4 / Glycogen storage disease 1B | 7 | 9.21% | | SLC37A4 / Glycogen storage disease 1D | 7 | 9.21% | | PDX1 / Maturity-onset diabetes of the young 4 | 7 | 9.21% | | PINK1 / Parkinson disease 6 | 7 | 9.21% | | ABCC9 / Intellectual disability and myopathy syndrome | 6 | 7.89% | | ABCC9 / Atrial fibrillation, familial, 12 | 6 | 7.89% | | ABCC9 / Cardiomyopathy, dilated, 1O | 6 | 7.89% | | ABCC9 / Hypertrichotic osteochondrodysplasia | 6 | 7.89% | | SLC12A3 / Gitelman syndrome | 6 | 7.89% | | SLC12A6 / Charcot-Marie-Tooth disease, axonal, type 2II | 6 | 7.89% | | ABCG5 / Sitosterolemia 2 | 6 | 7.89% | | SLC12A1 / Bartter syndrome 1, antenatal | 6 | 7.89% | | GATA1 / Anemia, congenital, non-spherocytic hemolytic, 9 | 6 | 7.89% | | GATA1 / Anemia without thrombocytopenia, X-linked | 6 | 7.89% | | GATA1 / X-linked dyserythropoietic anemia and thrombocytopenia | 6 | 7.89% | | GCK / Diabetes mellitus, permanent neonatal, 1 | 6 | 7.89% | | GCK / Hyperinsulinemic hypoglycemia, familial, 3 | 6 | 7.89% | | HK1 / Anemia, congenital, non-spherocytic hemolytic, 5 | 6 | 7.89% | | HK1 / Neurodevelopmental disorder with visual defects and brain anomalies | 6 | 7.89% | | HK1 / Neuropathy, hereditary motor and sensory, Russe type | 6 | 7.89% | | HK1 / Retinitis pigmentosa 79 | 6 | 7.89% | | HNF1A / Maturity-onset diabetes of the young 3 | 6 | 7.89% | | HNF1A / Type 1 diabetes mellitus 20 | 6 | 7.89% | | HNF1A / Hepatic adenomas familial | 6 | 7.89% | | ACSL4 / Intellectual developmental disorder, X-linked 63 | 6 | 7.89% | | CCNK / Intellectual developmental disorder with hypertelorism and distinctive facies | 6 | 7.89% | | ACSL4 / AMME complex | 6 | 7.89% | | PDX1 / Type 2 diabetes mellitus | 6 | 7.89% | | NKX2-1 / Chorea, hereditary benign | 6 | 7.89% | | TTC7A / Gastrointestinal defects and immunodeficiency syndrome 1 | 6 | 7.89% | | INS / Maturity-onset diabetes of the young 10 | 6 | 7.89% | | PPP1R3A / Type 2 diabetes mellitus | 6 | 7.89% | | GRHL2 / Ectodermal dysplasia/short stature syndrome | 6 | 7.89% | | SLC16A1 / Hyperinsulinemic hypoglycemia, familial, 7 | 5 | 6.58% | | ABCG8 / Sitosterolemia 1 | 5 | 6.58% | | SLC16A1 / Symptomatic deficiency in lactate transport | 5 | 6.58% | | GCK / Type 2 diabetes mellitus | 5 | 6.58% | | SLC37A4 / Congenital disorder of glycosylation 2W | 5 | 6.58% | | CYP1B1 / Anterior segment dysgenesis 6 | 5 | 6.58% | | TAF1 / Dystonia 3, torsion, X-linked | 5 | 6.58% | | TAF1 / Intellectual developmental disorder, X-linked, syndromic 33 | 5 | 6.58% | | ARNT2 / Webb-Dattani syndrome | 5 | 6.58% | | PPP1R13L / Arrhythmogenic cardiomyopathy with variable ectodermal abnormalities | 5 | 6.58% | | PDX1 / Pancreatic agenesis 1 | 5 | 6.58% | | ZNF462 / Weiss-Kruszka syndrome | 5 | 6.58% | | KCNJ11 / Maturity-onset diabetes of the young 13 | 5 | 6.58% | | SLC34A1 / Nephrolithiasis/osteoporosis, hypophosphatemic, 1 | 5 | 6.58% | | SLC34A1 / Fanconi renotubular syndrome 2 | 5 | 6.58% | | INS / Diabetes mellitus, permanent neonatal, 4 | 5 | 6.58% | | IRS1 / Type 2 diabetes mellitus | 5 | 6.58% | | TRIM8 / Focal segmental glomerulosclerosis and neurodevelopmental syndrome | 5 | 6.58% | | HNF1B / Type 2 diabetes mellitus | 5 | 6.58% | | FOXD3 / Autoimmune disease 1 | 5 | 6.58% | | HNF1B / Renal cysts and diabetes syndrome | 5 | 6.58% | | HNF1B / Prostate cancer, hereditary, 11 | 5 | 6.58% | | SLC22A12 / Hypouricemia renal 1 | 4 | 5.26% | | SLC16A1 / Monocarboxylate transporter 1 deficiency | 4 | 5.26% | | ZNF423 / Joubert syndrome 19 | 4 | 5.26% | | GCK / Maturity-onset diabetes of the young 2 | 4 | 5.26% | | EIF2AK1 / Leukoencephalopathy, motor delay, spasticity, and dysarthria syndrome | 4 | 5.26% | | SATB2 / Cleft palate isolated | 4 | 5.26% | | POLR2A / Neurodevelopmental disorder with hypotonia and variable intellectual and behavioral abnormalities | 4 | 5.26% | | FOXO1 / Rhabdomyosarcoma 2 | 4 | 5.26% | | CAPN10 / Type 2 diabetes mellitus 1 | 4 | 5.26% | | ZPR1 / Growth restriction, hypoplastic kidneys, alopecia, and distinctive facies | 4 | 5.26% | | SLC12A6 / Agenesis of the corpus callosum, with peripheral neuropathy | 4 | 5.26% | | SLC6A1 / Myoclonic-atonic epilepsy | 4 | 5.26% | | SLC25A15 / Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome | 4 | 5.26% | | RIPOR2 / Deafness, autosomal dominant, 21 | 4 | 5.26% | | SLC34A3 / Hereditary hypophosphatemic rickets with hypercalciuria | 4 | 5.26% | | IFT140 / Polycystic kidney disease 9 | 4 | 5.26% | | YIPF5 / Microcephaly, epilepsy, and diabetes syndrome 2 | 4 | 5.26% | | INS / Type 1 diabetes mellitus 2 | 4 | 5.26% | | INS / Hyperproinsulinemia | 4 | 5.26% | | HCK / Autoinflammation with pulmonary and cutaneous vasculitis | 4 | 5.26% | | TCF7L2 / Type 2 diabetes mellitus | 4 | 5.26% | | PHIP / Chung-Jansen syndrome | 4 | 5.26% | | WRAP53 / Dyskeratosis congenita, autosomal recessive, 3 | 4 | 5.26% | | TTI1 / Neurodevelopmental disorder with microcephaly and movement abnormalities | 4 | 5.26% | | NR5A1 / Spermatogenic failure 8 | 4 | 5.26% | | ABCC6 / Arterial calcification of infancy, generalized, 2 | 3 | 3.95% | | ABCC6 / Pseudoxanthoma elasticum | 3 | 3.95% | | ABCD1 / Adrenoleukodystrophy | 3 | 3.95% | | ABCB6 / Pseudohyperkalemia, familial, 2, due to red cell leak | 3 | 3.95% | | ABCB6 / Microphthalmia/Coloboma 7 | 3 | 3.95% | | ABCB6 / Dyschromatosis universalis hereditaria 3 | 3 | 3.95% | | CYP2U1 / Spastic paraplegia 56, autosomal recessive, with or without pseudoxanthoma elasticum | 3 | 3.95% | | SLC2A10 / Arterial tortuosity syndrome | 3 | 3.95% | | SOD1 / Amyotrophic lateral sclerosis 1 | 3 | 3.95% | | SLC4A1 / Renal tubular acidosis, distal, 4, with hemolytic anemia | 3 | 3.95% | | AKT2 / Type 2 diabetes mellitus | 3 | 3.95% | | AKT2 / Hypoinsulinemic hypoglycemia with hemihypertrophy | 3 | 3.95% | | SLC35A3 / Arthrogryposis, impaired intellectual development, and seizures | 3 | 3.95% | | DBT / Maple syrup urine disease 2 | 3 | 3.95% | | PGM1 / Congenital disorder of glycosylation 1T | 3 | 3.95% | | TALDO1 / Transaldolase deficiency | 3 | 3.95% | | POMT2 / Muscular dystrophy-dystroglycanopathy limb-girdle C2 | 3 | 3.95% | | POMT2 / Muscular dystrophy-dystroglycanopathy congenital with impaired intellectual development B2 | 3 | 3.95% | | RPIA / Ribose 5-phosphate isomerase deficiency | 3 | 3.95% | | POMT1 / Muscular dystrophy-dystroglycanopathy limb-girdle C1 | 3 | 3.95% | | POMT2 / Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A2 | 3 | 3.95% | | POMT1 / Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A1 | 3 | 3.95% | | CCND2 / Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 3 | 3 | 3.95% | | TWIST2 / Ablepharon-macrostomia syndrome | 3 | 3.95% | | TWIST2 / Focal facial dermal dysplasia 3, Setleis type | 3 | 3.95% | | SCO2 / Mitochondrial complex IV deficiency, nuclear type 2 | 3 | 3.95% | | TWIST2 / Barber-Say syndrome | 3 | 3.95% | | RRM2B / Rod-cone dystrophy, sensorineural deafness, and Fanconi-type renal dysfunction | 3 | 3.95% | | ZEB1 / Corneal dystrophy, posterior polymorphous, 3 | 3 | 3.95% | | ZEB1 / Corneal dystrophy, Fuchs endothelial, 6 | 3 | 3.95% | | PBX1 / Congenital anomalies of kidney and urinary tract syndrome with or without hearing loss, abnormal ears, or developmental delay | 3 | 3.95% | | LEF1 / Ectodermal dysplasia 17 with or without limb malformations | 3 | 3.95% | | GATA3 / Hypoparathyroidism, sensorineural deafness, and renal disease | 3 | 3.95% | | BLK / Maturity-onset diabetes of the young 11 | 3 | 3.95% | | PAX3 / Craniofacial-deafness-hand syndrome | 3 | 3.95% | | PAX3 / Waardenburg syndrome 1 | 3 | 3.95% | | PAX3 / Waardenburg syndrome 3 | 3 | 3.95% | | PAX6 / Keratitis hereditary | 3 | 3.95% | | PAX3 / Rhabdomyosarcoma 2 | 3 | 3.95% | | PAX6 / Foveal hypoplasia 1 | 3 | 3.95% | | ALPL / Hypophosphatasia | 3 | 3.95% | | NT5E / Calcification of joints and arteries | 3 | 3.95% | | ALPL / Hypophosphatasia, childhood | 3 | 3.95% | | FOXE3 / Anterior segment dysgenesis 2 | 3 | 3.95% | | KCNJ11 / Diabetes mellitus, permanent neonatal, 2 | 3 | 3.95% | | KCNJ11 / Diabetes mellitus, transient neonatal, 3 | 3 | 3.95% | | KCNJ11 / Hyperinsulinemic hypoglycemia, familial, 2 | 3 | 3.95% | | SLC24A5 / Albinism, oculocutaneous, 6 | 3 | 3.95% | | XK / McLeod syndrome | 3 | 3.95% | | SLC4A4 / Proximal renal tubular acidosis-ocular anomaly syndrome | 3 | 3.95% | | SLC34A1 / Hypercalcemia, infantile, 2 | 3 | 3.95% | | IFT140 / Cranioectodermal dysplasia 5 | 3 | 3.95% | | PDZD8 / Intellectual developmental disorder with autism and dysmorphic facies | 3 | 3.95% | | IFT140 / Short-rib thoracic dysplasia 9 with or without polydactyly | 3 | 3.95% | | IFT140 / Retinitis pigmentosa 80 | 3 | 3.95% | | DAP3 / Perrault syndrome 7 | 3 | 3.95% | | AVPR2 / Diabetes insipidus, nephrogenic, 1, X-linked | 3 | 3.95% | | AVPR2 / Nephrogenic syndrome of inappropriate antidiuresis | 3 | 3.95% | | GLI3 / Greig cephalo-poly-syndactyly syndrome | 3 | 3.95% | | INSR / Type 2 diabetes mellitus | 3 | 3.95% | | INSR / Insulin-resistant diabetes mellitus with acanthosis nigricans type A | 3 | 3.95% | | GCGR / Mahvash disease | 3 | 3.95% | | DDR2 / Warburg-Cinotti syndrome | 3 | 3.95% | | PHKB / Glycogen storage disease 9B | 3 | 3.95% | | SOX9 / Campomelic dysplasia | 3 | 3.95% | | AXIN1 / Craniometadiaphyseal osteosclerosis with hip dysplasia | 3 | 3.95% | | SOX10 / Waardenburg syndrome 2E | 3 | 3.95% | | SOX10 / Waardenburg syndrome 4C | 3 | 3.95% | | ESRRB / Deafness, autosomal recessive, 35 | 3 | 3.95% | | CARD11 / Immunodeficiency 11B with atopic dermatitis | 3 | 3.95% | | CARD11 / Immunodeficiency 11 A | 3 | 3.95% | | ARPC1B / Immunodeficiency 71 with inflammatory disease and congenital thrombocytopenia | 3 | 3.95% | | TRAPPC2 / Spondyloepiphyseal dysplasia tarda | 3 | 3.95% | | SASH1 / Cancer, alopecia, pigment dyscrasia, onychodystrophy, and keratoderma | 3 | 3.95% | | SASH1 / Dyschromatosis universalis hereditaria 1 | 3 | 3.95% | | TRIM2 / Charcot-Marie-Tooth disease, axonal, type 2R | 3 | 3.95% | | PPP1R15B / Microcephaly, short stature, and impaired glucose metabolism 2 | 3 | 3.95% | | RTN2 / Neuronopathy, distal hereditary motor, autosomal recessive 11, with spasticity | 3 | 3.95% | | KANK2 / Palmoplantar keratoderma and woolly hair | 3 | 3.95% | | FLCN / Birt-Hogg-Dube syndrome 1 | 3 | 3.95% | | STOX1 / Pre-eclampsia/eclampsia 4 | 3 | 3.95% | | TMC6 / Epidermodysplasia verruciformis 1 | 3 | 3.95% | | RIPOR2 / Deafness, autosomal recessive, 104 | 3 | 3.95% | | ZBTB7A / Macrocephaly, neurodevelopmental delay, lymphoid hyperplasia, and persistent fetal hemoglobin | 3 | 3.95% | | FKBP6 / Spermatogenic failure 77 | 3 | 3.95% | | HYCC1 / Leukodystrophy, hypomyelinating, 5 | 3 | 3.95% | | CP / Aceruloplasminemia | 3 | 3.95% | | MTOR / Smith-Kingsmore syndrome | 3 | 3.95% | | GALM / Galactosemia 4 | 3 | 3.95% | | ADA / Severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-negative/NK-cell-negative due to adenosine deaminase deficiency | 3 | 3.95% | | UCHL1 / Parkinson disease 5 | 3 | 3.95% | | UCHL1 / Spastic paraplegia 79B, autosomal recessive | 3 | 3.95% | | UCHL1 / Spastic paraplegia 79A, autosomal dominant, with ataxia | 3 | 3.95% | | SIGMAR1 / Neuronopathy, distal hereditary motor, autosomal recessive 2 | 3 | 3.95% | | TCF3 / Agammaglobulinemia 8B, autosomal recessive | 3 | 3.95% | | TCF3 / Agammaglobulinemia 8A, autosomal dominant | 3 | 3.95% | | GRHL2 / Deafness, autosomal dominant, 28 | 3 | 3.95% | | NR5A1 / 46,XY sex reversal 3 | 3 | 3.95% | | NR5A1 / Premature ovarian failure 7 | 3 | 3.95% | | NR5A1 / 46,XX sex reversal 4 | 3 | 3.95% | | GRHL2 / Corneal dystrophy, posterior polymorphous, 4 | 3 | 3.95% |

Phase 3: The Structural Bridge Theorem (Mapping)

The Type 1 & Type 2 Integration Matrices: The following nodes perfectly bridge both Type 1 (Autoimmune) and Type 2 (Metabolic) structures within their tightest computational horizons, proving physical intersection in structural space: - ABCC8 / Diabetes mellitus, permanent neonatal, 3 - ABCC8 / Transient neonatal diabetes mellitus 2 - ACSL4 / AMME complex - ACSL4 / Intellectual developmental disorder, X-linked 63 - ALPL / Hypophosphatasia - ALPL / Hypophosphatasia, childhood - ANGPTL8 / Type 1 diabetes mellitus - ANGPTL8 / Type 2 diabetes mellitus - ARL2BP / Retinitis pigmentosa 82 with or without situs inversus - ARNT2 / Webb-Dattani syndrome - ARPC1B / Immunodeficiency 71 with inflammatory disease and congenital thrombocytopenia - ARPC4 / Developmental delay, language impairment, and ocular abnormalities - ARV1 / Developmental and epileptic encephalopathy 38 - ATAD3A / Harel-Yoon syndrome - ATXN10 / Spinocerebellar ataxia 10 - BSCL2 / Lipodystrophy, congenital generalized, 2 - CAPN10 / Type 2 diabetes mellitus 1 - CARD11 / Immunodeficiency 11 A - CARD11 / Immunodeficiency 11B with atopic dermatitis - CAVIN1 / Lipodystrophy, congenital generalized, 4 - CCNK / Intellectual developmental disorder with hypertelorism and distinctive facies - CDK5 / Lissencephaly 7, with cerebellar hypoplasia - EIF2AK4 / Pulmonary venoocclusive disease 2, autosomal recessive - EPAS1 / Erythrocytosis, familial, 4 - FADD / Infections, recurrent, associated with encephalopathy, hepatic dysfunction and cardiovascular malformations - FKBP6 / Spermatogenic failure 77 - FLCN / Birt-Hogg-Dube syndrome 1 - FLCN / Primary spontaneous pneumothorax - FLCN / Renal cell carcinoma - GCGR / Mahvash disease - GCK / Diabetes mellitus, permanent neonatal, 1 - GCK / Hyperinsulinemic hypoglycemia, familial, 3 - GCK / Type 2 diabetes mellitus - GLI3 / Greig cephalo-poly-syndactyly syndrome - GRID2 / Spinocerebellar ataxia, autosomal recessive, 18 - HCK / Autoinflammation with pulmonary and cutaneous vasculitis - HJV / Hemochromatosis 2A - HK1 / Anemia, congenital, non-spherocytic hemolytic, 5 - HK1 / Neurodevelopmental disorder with visual defects and brain anomalies - HK1 / Neuropathy, hereditary motor and sensory, Russe type - HK1 / Retinitis pigmentosa 79 - HNF1A / Hepatic adenomas familial - HNF1A / Maturity-onset diabetes of the young 3 - HNF1A / Type 1 diabetes mellitus 20 - HNF4A / Fanconi renotubular syndrome 4 with maturity-onset diabetes of the young - HNF4A / Maturity-onset diabetes of the young 1 - HNF4A / Type 2 diabetes mellitus - HYCC1 / Leukodystrophy, hypomyelinating, 5 - IFT140 / Polycystic kidney disease 9 - IL2RA / Immunodeficiency 41 with lymphoproliferation and autoimmunity - IL2RA / Type 1 diabetes mellitus 10 - INS / Diabetes mellitus, permanent neonatal, 4 - INS / Hyperproinsulinemia - INS / Maturity-onset diabetes of the young 10 - INS / Type 1 diabetes mellitus 2 - INSR / Insulin-resistant diabetes mellitus with acanthosis nigricans type A - INSR / Type 2 diabetes mellitus - IRS1 / Type 2 diabetes mellitus - LRP5 / High bone mass trait - LRP5 / Osteopetrosis, autosomal dominant 1 - LRP5 / Osteoporosis-pseudoglioma syndrome - LRP5 / Van Buchem disease 2 - MAFA / Insulinomatosis and diabetes mellitus - MAPK8IP1 / Type 2 diabetes mellitus - MAPKAPK5 / Neurocardiofaciodigital syndrome - MEFV / Pyrin-associated autoinflammatory disease - MID1 / Opitz GBBB syndrome - NDNF / Hypogonadotropic hypogonadism 25 with anosmia - NEUROD1 / Maturity-onset diabetes of the young 6 - NEUROD1 / Type 2 diabetes mellitus - OTUD5 / Multiple congenital anomalies-neurodevelopmental syndrome, X-linked - PAX4 / Diabetes mellitus, ketosis-prone - PAX4 / Maturity-onset diabetes of the young 9 - PAX4 / Type 2 diabetes mellitus - PDE10A / Dyskinesia, limb and orofacial, infantile-onset - PINK1 / Parkinson disease 6 - POLR2A / Neurodevelopmental disorder with hypotonia and variable intellectual and behavioral abnormalities - PPP1R13L / Arrhythmogenic cardiomyopathy with variable ectodermal abnormalities - PPP1R15B / Microcephaly, short stature, and impaired glucose metabolism 2 - PPP1R3A / Type 2 diabetes mellitus - PRKD1 / Congenital heart defects and ectodermal dysplasia - PTGDR / Asthma-related traits 1 - PTPN11 / LEOPARD syndrome 1 - RD3 / Leber congenital amaurosis 12 - RIPOR2 / Deafness, autosomal dominant, 21 - RIPOR2 / Deafness, autosomal recessive, 104 - SATB2 / Cleft palate isolated - SIGMAR1 / Neuronopathy, distal hereditary motor, autosomal recessive 2 - SLC2A4 / Type 2 diabetes mellitus - SLC37A4 / Congenital disorder of glycosylation 2W - SLC37A4 / Glycogen storage disease 1B - SLC37A4 / Glycogen storage disease 1C - SLC37A4 / Glycogen storage disease 1D - SLC5A1 / Congenital glucose/galactose malabsorption - SLC5A2 / Renal glucosuria - SLITRK1 / Trichotillomania - STOX1 / Pre-eclampsia/eclampsia 4 - TAF1 / Dystonia 3, torsion, X-linked - TAF1 / Intellectual developmental disorder, X-linked, syndromic 33 - TMC6 / Epidermodysplasia verruciformis 1 - TMC8 / Epidermodysplasia verruciformis 2 - TMEM163 / Leukodystrophy, hypomyelinating, 25 - TRIM2 / Charcot-Marie-Tooth disease, axonal, type 2R - TRIM8 / Focal segmental glomerulosclerosis and neurodevelopmental syndrome - TRPM6 / Hypomagnesemia 1 - TTC7A / Gastrointestinal defects and immunodeficiency syndrome 1 - TTI1 / Neurodevelopmental disorder with microcephaly and movement abnormalities - UCHL1 / Parkinson disease 5 - UCHL1 / Spastic paraplegia 79A, autosomal dominant, with ataxia - UCHL1 / Spastic paraplegia 79B, autosomal recessive - XPNPEP3 / Nephronophthisis-like nephropathy 1 - ZBTB7A / Macrocephaly, neurodevelopmental delay, lymphoid hyperplasia, and persistent fetal hemoglobin - ZNF462 / Weiss-Kruszka syndrome

Phase 4: Foundational Epistemology (Systemic Convergence)

The Universal Convergence Anchors: - CTLA4: Mathematically converged in 76 distinct diabetes analyses (100% Stable Lock). - FUS: Mathematically converged in 76 distinct diabetes analyses (100% Stable Lock). - INSR: Mathematically converged in 76 distinct diabetes analyses (100% Stable Lock). - DMD: Mathematically converged in 76 distinct diabetes analyses (100% Stable Lock). - FGB: Mathematically converged in 76 distinct diabetes analyses (100% Stable Lock). - FGA: Mathematically converged in 76 distinct diabetes analyses (100% Stable Lock). - FGG: Mathematically converged in 76 distinct diabetes analyses (100% Stable Lock). - PLG: Mathematically converged in 76 distinct diabetes analyses (100% Stable Lock).

Phase 5 & 6: Operational Directives & Next Steps

plane_invert: Utilize the shared structural backbone (NEUROD1, PAX4, SLC2A4) as the verified base geometry for testing novel broad-spectrum diabetic therapies.
Model-Specific Assays: Target the bridging geometries (e.g., GCK, IL2RA) in vitro to test if resolving the Type 2 osmotic pressure physically aborts the Type 1 autoimmune T-cell signaling cascade.